The drug, Emestedastat (brand name Xanamem), is being developed by Australian biotechnology company Actinogen. It works by blocking production of cortisol in key brain areas linked to the progression of Alzheimer's disease.
The 36-week double-blind, placebo-controlled trial did not record a statistically significant benefit across the entire group. However, participants aged over the median age of 75, half of the cohort, experienced a 30% slowing of disease progression by the end of the trial.
Dr Steven Gourlay, CEO of Actinogen, said the results in over-75s compared favourably with recently approved monoclonal antibody treatments for Alzheimer's, which reduce progression by between 22 and 27 per cent. “Nobody's really developing anything for the older patients who are a bit more severe and more advanced,” he said. “Our drug probably is having an effect of lowering inflammation in the brain because patients who are older also have higher markers of inflammation.”
Gourlay acknowledged it was disappointing the drug did not show the same benefit in younger patients, but pointed to the advantages of a low-dose oral tablet that would cost significantly less and have fewer side effects than current therapies.
Professor Michael Woodward, honorary medical adviser for Dementia Australia, said it was typical for dementia drug trials to have mixed results, but the findings could help shape the next phase of trials. “We know that cortisol is really important for dementia,” he said. “And we know that blocking it is a way of preventing some of the changes we see in Alzheimer's.”
The results emerged on the same day that University of Sydney researchers reported developing experimental nose drops that use mRNA technology to boost cognition and prevent memory loss in mice carrying genetic mutations for Alzheimer's. Study author Professor Greg Neely said the drops blocked cognitive decline and dementia in mice. “We think this drug may be able to convert a dementia sensitive participant into a dementia resilient one,” he said. Human trials are the next step.
The development comes amid heightened activity in Alzheimer's treatment. World-first drugs that actively interfere with the disease's progression were approved in Australia last year, along with a pioneering blood test for diagnosis. The monoclonal antibodies donanemab and lecanemab work by reducing amyloid beta plaque buildup. Another drug, Xanamem, targets cortisol. While cortisol production is normal and necessary, the hypothesis is that if levels remain high for a long time, it can become toxic to neurons.
Sydneysider Richard Davies, 61, who was diagnosed with young-onset Alzheimer's last year and is a Dementia Australia advocate, has been treated with donanemab. He believes it should be subsidised. “I'm seeing genuine progress in the field and there's certainly plenty of work going on,” he said. “The upside is that the science and medicine is getting better all the time.”
The next trial for Xanamem is expected to involve 700 patients and get under way mid-next year, with the company hoping to bring the drug to market in 2030.
